Business Wire | Nov 9, 2021 07:15AM EST

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov. 09, 2021

LAUSANNE, Switzerland--(BUSINESS WIRE)--Nov. 09, 2021--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, PhD, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 16th at 11:20 a.m. GMT / 6:20 a.m. EST.

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics' CD19-directed ADC ZYNLONTA(r) (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a late-stage clinical trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA(r) is a registered trademark of ADC Therapeutics SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005902/en/

CONTACT: Investors Eugenia Litz ADC Therapeutics Eugenia.Litz@adctherapeutics.com +44 7879 627205

CONTACT: Amanda Hamilton ADC Therapeutics amanda.hamilton@adctherapeutics.com +1 917-288-7023

CONTACT: EU Media Alexandre Mller Dynamics Group amu@dynamicsgroup.ch +41 (0) 43 268 3231

CONTACT: USA Media Mary Ann Ondish ADC Therapeutics maryann.ondish@adctherapeutics.com Tel.: +1 914-552-4625